AstraZeneca PLC (AZN)vsChemed Corp (CHE)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
CHE
Chemed Corp
$424.98
+0.25%
HEALTHCARE · Cap: $5.69B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 2212% more annual revenue ($58.74B vs $2.54B). AZN leads profitability with a 17.4% profit margin vs 10.2%. AZN appears more attractively valued with a PEG of 1.54. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
CHE
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
-36.8%
Fair Value
$338.44
Current Price
$424.98
$86.54 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Safe zone — low bankruptcy risk
Every $100 of equity generates 26 in profit
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Expensive relative to growth rate
1.6% revenue growth
Weak financial health signals
Earnings declined 0.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : CHE
The strongest argument for CHE centers on Altman Z-Score, Return on Equity, Debt/Equity.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : CHE
The primary concerns for CHE are PEG Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
CHE carries more volatility with a beta of 0.48 — expect wider price swings.
AZN is growing revenue faster at 4.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (64/100 vs 51/100), backed by strong 17.4% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Chemed Corp
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Chemed Corporation provides hospice and hospice services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers across the United States. The company is headquartered in Cincinnati, Ohio.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?